These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 10745257)
1. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257 [TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
3. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931 [TBL] [Abstract][Full Text] [Related]
4. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Gertz MA; Lacy MQ; Inwards DJ; Gastineau DA; Tefferi A; Chen MG; Witzig TE; Greipp PR; Litzow MR Bone Marrow Transplant; 2000 Jul; 26(1):45-50. PubMed ID: 10918404 [TBL] [Abstract][Full Text] [Related]
5. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592 [TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J; Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267 [TBL] [Abstract][Full Text] [Related]
7. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
9. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252 [TBL] [Abstract][Full Text] [Related]
10. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
11. [Autologous peripheral blood stem cell transplantation for Japanese multiple myeloma patients: results of a feasibility study]. Nakamura Y; Sakamaki H; Mukai H; Kojima H; Tomiyama J; Mori S; Hiruma K; Nakamura N; Toyota S; Hamaguchi H; Dans K; Mitani K; Saito K Rinsho Ketsueki; 2004 Jul; 45(7):524-9. PubMed ID: 15359911 [TBL] [Abstract][Full Text] [Related]
12. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284 [TBL] [Abstract][Full Text] [Related]
13. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574 [TBL] [Abstract][Full Text] [Related]
14. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma. Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102 [TBL] [Abstract][Full Text] [Related]
17. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815 [TBL] [Abstract][Full Text] [Related]
18. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563 [TBL] [Abstract][Full Text] [Related]
19. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786 [TBL] [Abstract][Full Text] [Related]
20. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]